Raloxifene Hydrochloride Tablet, Film Coated
Product Images NDC 68462-393

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 68462-393). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Raloxifene Hydrochloride Usp Chemical Structure (Image 01)

Raloxifene Hydrochloride Usp Chemical Structure (Image 01)
Chemical structure of raloxifene hydrochloride, the active ingredient depicted in the diagram, showing its molecular arrangement including aromatic rings, functional groups, and hydrochloride salt.*
FDA Label Image

Total Hip Mean Percentage Change From Baseline: All Placebo And Raloxifene Hydrochloride Subjects 24 Months Data From Studies Na And Eu (Image 02)

Total Hip Mean Percentage Change From Baseline: All Placebo And Raloxifene Hydrochloride Subjects 24 Months Data From Studies Na And Eu (Image 02)
A line graph depicting percentage change over 24 months after randomization, comparing raloxifene hydrochloride and placebo groups. The x-axis represents months after randomization, while the y-axis shows percentage change. Data lines show raloxifene hydrochloride with a positive trend and placebo with a negative trend.*
FDA Label Image

Total Hip Mean Percentage Change From Baseline (All placebo, Raloxifene Hydrochloride and CE subjects 24-month data from Study INT (hysterectomized women))

Total Hip Mean Percentage Change From Baseline (All placebo, Raloxifene Hydrochloride and CE subjects 24-month data from Study INT (hysterectomized women))
A line chart showing percentage change over 24 months after randomization comparing raloxifene hydrochloride, placebo, and conjugated estrogens (CE 0.625 mg/day). The vertical axis represents percentage change, and the horizontal axis represents months after randomization. The chart includes error bars for each data point.*
FDA Label Image

Image 04

Image 04
Label for Raloxifene Hydrochloride Tablets USP 60 mg, film-coated oral tablets. The label indicates a package size of 100 tablets and is marked as Rx Only. It includes storage instructions, manufacturer Glenmark Pharmaceuticals Inc., USA, and distributor Glenmark Pharmaceuticals Ltd., India. Barcode and contact details for Glenmark are also visible.*
FDA Label Image

Image 06

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.